Valneva Eyes Head-to-Head Vaccine Trial

Feb.05 — Thomas Lingelbach, chief executive officer at Valneva SE, discusses the company’s vaccine trials, the difference in processes in working with the U.K. versus the EU and production of the vaccine. He speaks on “Bloomberg Markets: European Open.”